Bevacizumab in older patients with advanced colorectal or breast cancer
G Aprile, L Ferrari, C Fontanella, F Puglisi - Critical Reviews in Oncology …, 2013 - Elsevier
The incidence of colorectal and breast cancer is growing among the 550 million living
people aged 65 or older. Bevacizumab was the first anti-angiogenic agent approved for the …
people aged 65 or older. Bevacizumab was the first anti-angiogenic agent approved for the …
Bevacizumab in older patients with advanced colorectal or breast cancer
G Aprile, L Ferrari, C Fontanella, F Puglisi - CRITICAL REVIEWS IN …, 2013 - air.uniud.it
The incidence of colorectal and breast cancer is growing among the 550 million living
people aged 65 or older. Bevacizumab was the first anti-angiogenic agent approved for the …
people aged 65 or older. Bevacizumab was the first anti-angiogenic agent approved for the …
Bevacizumab in older patients with advanced colorectal or breast cancer
G Aprile, L Ferrari, C Fontanella, F Puglisi - Critical Reviews in Oncology …, 2013 - infona.pl
The incidence of colorectal and breast cancer is growing among the 550 million living
people aged 65 or older. Bevacizumab was the first anti-angiogenic agent approved for the …
people aged 65 or older. Bevacizumab was the first anti-angiogenic agent approved for the …
Bevacizumab in older patients with advanced colorectal or breast cancer
G Aprile, L Ferrari, C Fontanella, F Puglisi - 2013 - ricerca.unityfvg.it
The incidence of colorectal and breast cancer is growing among the 550 million living
people aged 65 or older. Bevacizumab was the first anti-angiogenic agent approved for the …
people aged 65 or older. Bevacizumab was the first anti-angiogenic agent approved for the …
[PDF][PDF] Bevacizumab in older patients with advanced colorectal or breast cancer
G Aprilea, L Ferraria, C Fontanellaa… - Critical Reviews in …, 2013 - academia.edu
The incidence of colorectal and breast cancer is growing among the 550 million living
people aged 65 or older. Bevacizumab was the first anti-angiogenic agent approved for the …
people aged 65 or older. Bevacizumab was the first anti-angiogenic agent approved for the …
Bevacizumab in older patients with advanced colorectal or breast cancer.
G Aprile, L Ferrari, C Fontanella… - Critical Reviews in …, 2012 - europepmc.org
The incidence of colorectal and breast cancer is growing among the 550 million living
people aged 65 or older. Bevacizumab was the first anti-angiogenic agent approved for the …
people aged 65 or older. Bevacizumab was the first anti-angiogenic agent approved for the …
Bevacizumab in older patients with advanced colorectal or breast cancer
G Aprile, L Ferrari, C Fontanella… - Critical reviews in …, 2013 - pubmed.ncbi.nlm.nih.gov
The incidence of colorectal and breast cancer is growing among the 550 million living
people aged 65 or older. Bevacizumab was the first anti-angiogenic agent approved for the …
people aged 65 or older. Bevacizumab was the first anti-angiogenic agent approved for the …
Bevacizumab in older patients with advanced colorectal or breast cancer
G Aprile, L Ferrari, C Fontanella, F Puglisi - 2013 - ricerca.unityfvg.it
The incidence of colorectal and breast cancer is growing among the 550 million living
people aged 65 or older. Bevacizumab was the first anti-angiogenic agent approved for the …
people aged 65 or older. Bevacizumab was the first anti-angiogenic agent approved for the …